OpGen Inc Gets a Buy Rating from H.C. Wainwright


In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on OpGen Inc (NASDAQ: OPGN), with a price target of $9. The company’s shares closed yesterday at $1.90, close to its 52-week low of $1.62.

According to TipRanks.com, Selvaraju is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -5.8% and a 37.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.

OpGen Inc has an analyst consensus of Moderate Buy, with a price target consensus of $9.

See today’s analyst top recommended stocks >>

The company has a one-year high of $22.50 and a one-year low of $1.62. Currently, OpGen Inc has an average volume of 523K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

OpGen, Inc. is a precision medicine company, which engages in the development of molecular information products and services to combat infectious disease in global healthcare settings, helping to guide clinicians with rapid information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resist

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts